Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 6, 2013, Pages 640-646

  De Boer, Y S ^a   Van Gerven, N M F ^a   De Boer, N K H ^a   Mulder, C J J ^a   Bouma, G ^a   Van Nieuwkerk, C M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 TIOGUANINE NUCLEOTIDE; ALANINE AMINOTRANSFERASE; ALLOPURINOL; AZATHIOPRINE; BUDESONIDE; DRUG METABOLITE; MERCAPTOPURINE; METHYLMERCAPTOPURINE; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAND PARESTHESIA; HUMAN; HYPERESTHESIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MYALGIA; NAUSEA; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTE COUNT; VOMITING;

6-MERCAPTOPURINE; ADULT; AGED; ALANINE TRANSAMINASE; ALLOPURINOL; ANTIMETABOLITES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; METHYLTRANSFERASES; MIDDLE AGED; SALVAGE THERAPY; THIOGUANINE;

EID: 84874117085     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12223     Document Type: Article

References (21)

1. Manns MP, Czaja AJ, Gorham JD, et al,. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
2. Gleeson D, Heneghan MA,. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-29.
3. De Boer NK, Van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ,. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 686-94.
4. Lennard L, Singleton HJ,. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992; 583: 83-90.
5. Weinshilboum R,. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 601-5.
6. Dubinsky MC, Lamothe S, Yang HY, et al,. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
7. Sparrow MP, Hande SA, Friedman S, et al,. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22: 441-6.
8. Hoentjen F, Seinen ML, Hanauer SB, et al,. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2012; doi: 10.1002/ibd.23021 [Epub ahead of print].
9. Ansari A, Patel N, Sanderson J, et al,. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-7.
10. Dervieux T, Boulieu R,. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998; 44: 551-5.
11. Lennard L,. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987; 423: 169-178.
12. Shipkova M, Armstrong VW, Wieland E, Oellerich M,. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003; 49: 260-8.
13. Alvarez F, Berg PA, Bianchi FB, et al,. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
14. Azulay JP, Blin O, Valentin P, et al,. Regression of allopurinol-induced peripheral neuropathy after drug withdrawal. Eur Neurol 1993; 33: 193-4.
15. Dhaliwal HK, Anderson R, Thornhill EL, et al,. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 2012; 56: 1401-8.
16. Czaja AJ,. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci 2012; 57: 1996-2010.
17. Hennes EM, Oo YH, Schramm C, et al,. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-70.
18. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al,. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34: 335-43.
19. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN,. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011; 55: 636-46.
20. Heneghan MA, Al-Chalabi T, McFarlane IG,. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 2006; 7: 145-56.
21. Hesselink DA, Bouamar R, van Gelder T,. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010; 32: 387-93.